Mutations in CNS tumors

 

Key points:

1. MGMT promoter methylation predicts response to alkylator treatment in IDH WT GBM, not in IDH mutant.

2. EGFR mutations in CNS disease have not been amenable to anti-EGFR treatment

3. ATRX loss to be a highly specific biomarker of astrocytic lineage

4. ATRX loss is mutually exclusive from 1p/19q co-deletion in oligodendroglioma

5. IDH WT has a worse prognosis

Reference:

1. https://www.sciencedirect.com/science/article/pii/S0716864017300603?via%3Dihub

2. 4 prognostic categories based on molecular markers